A study led by researchers at the University of Pennsylvania has found that binary (yes/no) voting at the FDA Oncologic Drugs Advisory Committee can accurately capture the committee members’ perspectives in most cases.
Rick Pazdur, MD, the newly appointed director for the Center for Drug Evaluation and Research at the FDA, has been described as “greyhound thin” as a result of his dedication to cycling and lifting weights in the gym each day and, for a long time, a vegetarian diet. I first met him when he was the director of the Office of Oncology Drug Products (ODP) within CDER, in 2009.
